Ultra-sensitive Singlet Oxygen Dosimeter for Skin Cancer Treatment and Prevention

用于皮肤癌治疗和预防的超灵敏单线态氧剂量计

基本信息

  • 批准号:
    10010539
  • 负责人:
  • 金额:
    $ 40万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-06 至 2021-04-30
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Skin cancer is the most common form of cancer. Each year in the U.S. alone over 5.4 million cases of nonmelanoma skin cancer are treated. The annual cost of treating skin cancers in the U.S. is estimated at $8.1 billion. Treatment and prevention of skin cancer is a significant health care challenge. Physical Sciences Inc. (PSI), in collaboration with Dartmouth College and Cleveland Clinic, proposes to develop a novel optical dosimetry technology and demonstrate its applications in two areas, i.e., real-time measurement of photosensitizer (PS) and singlet oxygen (O2) during photodynamic therapy (PDT), and non-invasive quantification of singlet O2 produced in skin under UV irradiation. This ultrasensitive, robust dosimeter is based on an innovative “computational spectroscopy” technology and a low-cost hardware configuration. We propose to demonstrate the capability of the singlet O2 dosimeter to guide optimization of PDT protocols for improved skin cancer treatment, as well as to support biomedical research focused on understanding skin damage/carcinogenesis by solar UV irradiation with a goal of accelerating the development of more effective sunscreen products. PDT is a targeted, minimally invasive treatment option for skin cancer. During PDT, singlet oxygen (O2) is produced and is responsible for the cell destruction. At the present time it is difficult, if not impossible, to predict the response of an individual to PDT. Solar UV irradiation causes direct DNA damage and thus skin carcinogenesis. UV irradiation on the skin also generates reactive oxygen species (ROS) including singlet O2, which also contributes to DNA damage. However, the carcinogenesis of ROS produced by UVA is not well understood, hindering developing more effective sunscreen products that protect against UVA and longer wavelengths. Real-time quantification of singlet O2 will benefit both applications, which, in turn, will lead to advancements in skin cancer therapy and prevention. The overall aim of the proposed Fast Track program is to develop and demonstrate the proposed real-time singlet O2 dosimetry technology. PSI will work with Dartmouth Hitchcock Hospital and Cleveland Clinic to demonstrate its application in both PDT and UV skin damage investigations. Beiersdorf, a major producer of skin care products will participate as a consultant at no cost to the program. Phase I will focus on demonstrating the feasibility of the proposed technology, by developing two prototypes and testing them on small scale in vivo (mice) and ex-vivo (human skin) experiments. During Phase II, the prototypes will be optimized and the improved Gen-2 prototypes will be distributed to three institutes for independent testing during large-scale animal studies and limited human patient testing. Successful completion of these tasks will lead to a noninvasive, robust singlet O2/PS dosimeter that could benefit research and clinical practice for curing and preventing skin cancer.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Youbo Zhao其他文献

Youbo Zhao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Youbo Zhao', 18)}}的其他基金

Ultra-sensitive Singlet Oxygen Dosimeter for Skin Cancer Treatment and Prevention
用于皮肤癌治疗和预防的超灵敏单线态氧剂量计
  • 批准号:
    10438940
  • 财政年份:
    2021
  • 资助金额:
    $ 40万
  • 项目类别:
Ultra-sensitive Singlet Oxygen Dosimeter for Skin Cancer Treatment and Prevention
用于皮肤癌治疗和预防的超灵敏单线态氧剂量计
  • 批准号:
    10425539
  • 财政年份:
    2021
  • 资助金额:
    $ 40万
  • 项目类别:
Optical Redox Probe for Continuous Metabolic Monitoring during Natural Products Bioprocessing
用于天然产品生物加工过程中连续代谢监测的光学氧化还原探针
  • 批准号:
    10480179
  • 财政年份:
    2019
  • 资助金额:
    $ 40万
  • 项目类别:
Advanced Intraoperative Imager for Nerve Identification
用于神经识别的先进术中成像仪
  • 批准号:
    10594515
  • 财政年份:
    2019
  • 资助金额:
    $ 40万
  • 项目类别:
Optical Redox Probe for Continuous Metabolic Monitoring during Natural Products Bioprocessing
用于天然产品生物加工过程中连续代谢监测的光学氧化还原探针
  • 批准号:
    10687154
  • 财政年份:
    2019
  • 资助金额:
    $ 40万
  • 项目类别:
Optical Redox Probe for Continuous Metabolic Monitoring during Natural Products Bioprocessing
用于天然产品生物加工过程中连续代谢监测的光学氧化还原探针
  • 批准号:
    9907720
  • 财政年份:
    2019
  • 资助金额:
    $ 40万
  • 项目类别:
Advanced Intraoperative Imager for Nerve Identification
用于神经识别的先进术中成像仪
  • 批准号:
    10481320
  • 财政年份:
    2019
  • 资助金额:
    $ 40万
  • 项目类别:
Supplemental support for the development of high spatiotemporal resolution neuronal imager
对高时空分辨率神经元成像仪开发的补充支持
  • 批准号:
    10879866
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
High Spatiotemporal Resolution Neural Recording System Using Active Sensing
使用主动传感的高时空分辨率神经记录系统
  • 批准号:
    10591614
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
High Spatiotemporal Resolution Neural Recording System Using Active Sensing
使用主动传感的高时空分辨率神经记录系统
  • 批准号:
    10481444
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:

相似海外基金

A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
一项 2 期、随机、双盲、4 组、多中心研究,旨在证明处方药局部剂量制剂治疗光化性角化病的有效性和安全性
  • 批准号:
    10820810
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
研究性新药使研究能够开发局部固定剂量组合药物产品,以治疗光化性角化病和预防皮肤鳞状细胞癌。
  • 批准号:
    10482509
  • 财政年份:
    2022
  • 资助金额:
    $ 40万
  • 项目类别:
Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis
光化性角化病患者的皮肤癌风险和风险预测
  • 批准号:
    10448977
  • 财政年份:
    2022
  • 资助金额:
    $ 40万
  • 项目类别:
Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis
光化性角化病患者的皮肤癌风险和风险预测
  • 批准号:
    10610895
  • 财政年份:
    2022
  • 资助金额:
    $ 40万
  • 项目类别:
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
研究性新药使研究能够开发局部固定剂量组合药物产品,以治疗光化性角化病和预防皮肤鳞状细胞癌。
  • 批准号:
    10701001
  • 财政年份:
    2022
  • 资助金额:
    $ 40万
  • 项目类别:
MTAK - Microwave Therapy for Actinic Keratosis
MTAK - 光化性角化病的微波疗法
  • 批准号:
    103352
  • 财政年份:
    2017
  • 资助金额:
    $ 40万
  • 项目类别:
    Collaborative R&D
From actinic keratosis to invasive squamous cell carcinoma: Impact of AHR and p27KIP1 on malignant transformation
从光化性角化病到浸润性鳞状细胞癌:AHR 和 p27KIP1 对恶性转化的影响
  • 批准号:
    511942584
  • 财政年份:
  • 资助金额:
    $ 40万
  • 项目类别:
    Research Units
PHARMACOLOGY OF VITAMIN A IN PATIENTS WITH ACTINIC KERATOSIS
维生素 A 在光化性角化病患者中的药理学
  • 批准号:
    4691509
  • 财政年份:
  • 资助金额:
    $ 40万
  • 项目类别:
PHARMACOLOGY OF VITAMIN A IN PATIENTS WITH ACTINIC KERATOSIS
维生素 A 在光化性角化病患者中的药理学
  • 批准号:
    3962586
  • 财政年份:
  • 资助金额:
    $ 40万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了